Paper · 34656226

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.

Yoo C and 11 others. Lancet Oncol, 2021. Cited by 185 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Papers, record 34656226. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34656226

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.; PubMed
Journal: Lancet Oncol; PubMed
Year: 2021; PubMed
Publication types: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/34656226/; PubMed
DOI: https://doi.org/10.1016/s1470-2045(21)00486-1; PubMed
The journal: https://conductscience.org/library/journal-index/100957246; PubMed
Citations, by iCite: 185; iCite
Relative citation ratio, by iCite: 11.4; iCite
Revised in PubMed: 2022-12-07; PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Yoo C	Changhoon
2	Kim KP	Kyu-Pyo
3	Jeong JH	Jae Ho
4	Kim I	Ilhwan
5	Kang MJ	Myoung Joo
6	Cheon J	Jaekyung
7	Kang BW	Byung Woog
8	Ryu H	Hyewon
9	Lee JS	Ji Sung
10	Kim KW	Kyung Won

1 to 10 of 12Source PubMed

See all 12 authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Combined Chemotherapy Protocols	Major topic
Biliary Tract Neoplasms	Major topic
Fluorouracil	Major topic
Irinotecan	Major topic
Leucovorin	Major topic
Adult
Aged
Aged, 80 and over
Cisplatin
Deoxycytidine
Disease Progression
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Progression-Free Survival
Republic of Korea
Survival Rate
Topoisomerase I Inhibitors
Gemcitabine

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT03524508	Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer	Derived from the trial	Yes	ClinicalTrials.gov
NCT06135896	Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers	Results		ClinicalTrials.gov
NCT06662877	Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment	Background		ClinicalTrials.gov

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Associated dataset	34,973,222	Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.	https://conductscience.org/library/papers/34973222	PubMed
Comment in	34,656,228	Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer.	https://conductscience.org/library/papers/34656228	PubMed
Comment in	34,973,221	Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.	https://conductscience.org/library/papers/34973221	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by117

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.

PMID	Title	Journal	Year	In Papers	Source
42,918,853	Intrahepatic cholangiocarcinoma: contemporary classification, molecular pathology, and emerging concepts.	Virchows Arch	2026	https://conductscience.org/library/papers/42918853	PubMed
42,875,757	Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2).	BMC Cancer	2026	https://conductscience.org/library/papers/42875757	PubMed
42,599,167	A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.	Clin Cancer Res	2026	https://conductscience.org/library/papers/42599167	PubMed
42,583,126	Third-line treatment of biliary tract cancers in a real-life setting.	ESMO Gastrointest Oncol	2026	https://conductscience.org/library/papers/42583126	PubMed
42,406,651	Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes.	Acta Haematol	2026	https://conductscience.org/library/papers/42406651	PubMed
42,360,806	Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.	Clin Cancer Res	2026	https://conductscience.org/library/papers/42360806	PubMed
41,783,112	Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions.	ESMO Gastrointest Oncol	2026	https://conductscience.org/library/papers/41783112	PubMed
41,756,323	Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.	Front Oncol	2026	https://conductscience.org/library/papers/41756323	PubMed
41,668,195	Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma.	Cost Eff Resour Alloc	2026	https://conductscience.org/library/papers/41668195	PubMed
41,648,028	Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin/gemcitabine: a systematic review and meta-analysis.	ESMO Gastrointest Oncol	2024	https://conductscience.org/library/papers/41648028	PubMed

1 to 10 of 117

See all 117 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
FOLINIC ACID	CHEMBL1232801	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL1232801	ChEMBL
FLUOROURACIL	CHEMBL185	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL185	ChEMBL
IRINOTECAN	CHEMBL481	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL481	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34656226

GET https://conductscience.org/api/papers/v1/34656226/cited_by?page=2

API reference For AI assistants